Key Highlights
● ImmunityBio climbed on Friday, trading at about $10.60 by mid-morning as cancer-focused biotech stocks rallied.
● No company-specific news explained the gain, and ImmunityBio was not named in connection with the NIH plan.
● ImmunityBio's best-known product is Anktiva, approved in the United States for a form of bladder cancer.
● Iovance Biotherapeutics and PDS Biotechnology also rallied, as did Moderna, which jumped $28.00 to $225.00.
ImmunityBio (NASDAQ:IBRX) climbed on Friday, trading at about $10.60 by mid-morning as cancer-focused biotech stocks rallied. No company-specific news explained the gain. The move fitted a pattern seen across the sector, as investors reacted to a media report that put cancer vaccines in the spotlight.
The report said the National Institutes of Health plans a public-private initiative, beginning in December, to fast-track research into cancer vaccines and treatments. According to the report, the first targets would include pancreatic, liver and colorectal cancers and some childhood tumors, with the aim of repeating the success of the Covid-19 Vaccine effort.
Why ImmunityBio caught a bid
ImmunityBio develops immunotherapies that aim to harness the body's own immune system against cancer and infectious disease. Its best-known product is Anktiva, approved in the United States for a form of bladder cancer, and the company is testing its technology in other tumor types. That focus on immune-based cancer treatment made it a natural candidate for investors looking for exposure to the cancer-vaccine theme, even though ImmunityBio was not named in connection with the NIH plan.
The rally reflected sentiment rather than any new data or partnership. As reported, the NIH initiative remains in the planning stage, and it has not been disclosed which companies, if any, would participate or how funding would be structured.
A broad biotech rally
The biggest gains came from vaccine developers. Moderna (NASDAQ:MRNA) jumped $28.00 to close at $225.00, its highest level since 2021, on the same day it officially joined the Nasdaq-100. Novavax (NASDAQ:NVAX) soared, and BioNTech (NASDAQ:BNTX), Arcturus Therapeutics (NASDAQ:ARCT) and Vaxcyte (NASDAQ:PCVX) also rallied. Larger drugmakers including Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD) rose too.
Other cancer and immunotherapy names moved alongside ImmunityBio. Iovance Biotherapeutics (NASDAQ:IOVA), which develops cell therapies for solid tumors, rallied, and small-cap PDS Biotechnology (NASDAQ:PDSB) also climbed. Genomics and tools stocks, including Illumina (NASDAQ:ILMN), 10x Genomics (NASDAQ:TXG) and Twist Bioscience (NASDAQ:TWST), gained as well. Health care was among the S&P 500's strongest sectors on Friday and finished among the leaders for the week.
Broader market
Stocks rose. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, just shy of Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. The Russell 2000 rose 12.85 points to 2,806.98, though it still posted a fifth straight weekly loss. On the Nasdaq, 2,756 issues advanced and 1,997 declined.
The macro backdrop remained a hurdle for development-stage biotech companies that depend on Capital Markets for funding. The 10-year Treasury Yield held near a 24-year high, the Fed raised rates in September for the first time since 2023, and Fed Governor Christopher Waller said: "For at least the near term, policy will be focused on the Inflation side of our mandate." The University of Michigan's preliminary October consumer sentiment index slipped to 46.3, a five-month low.
"It's the kind of back-and-forth market we've been in where we have the Reversal of sentiment around Iran," Ross Mayfield, Investment strategy analyst at Baird, said, capturing the stop-start mood that has made sector themes like Friday's vaccine trade so powerful.
NIH Details and ImmunityBio's Clinical or Commercial Updates Are the Next Items to Watch
Monday, October 12 is Columbus Day, with stocks open and the Bond Market closed. September consumer prices are due Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Official NIH details ahead of the expected December start, plus any clinical or commercial update from ImmunityBio, are the next items to watch.






Please wait processing your request...